Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Amortization of Deferred Charges (2016 - 2025)

Mimedx's Amortization of Deferred Charges history spans 13 years, with the latest figure at $135000.0 for Q1 2025.

  • For Q1 2025, Amortization of Deferred Charges rose 95.65% year-over-year to $135000.0; the TTM value through Mar 2025 reached $464000.0, up 2.43%, while the annual FY2023 figure was $505000.0, 8.14% up from the prior year.
  • Amortization of Deferred Charges for Q1 2025 was $135000.0 at Mimedx, up from $69000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $418000.0 in Q2 2021 and bottomed at $69000.0 in Q1 2024.
  • The 5-year median for Amortization of Deferred Charges is $120000.0 (2022), against an average of $159357.1.
  • The largest YoY upside for Amortization of Deferred Charges was 109.0% in 2021 against a maximum downside of 75.91% in 2021.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $112000.0 in 2021, then grew by 6.25% to $119000.0 in 2022, then increased by 10.92% to $132000.0 in 2023, then crashed by 47.73% to $69000.0 in 2024, then surged by 95.65% to $135000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Amortization of Deferred Charges are $135000.0 (Q1 2025), $69000.0 (Q1 2024), and $132000.0 (Q4 2023).